Articles tagged with “health-economics”

Learn about value-based contracting (VBC) in pharma. Our guide covers how these agreements tie drug reimbursement to patient outcomes, key data requirements, an

Efficacy in clinical trials often overstates real-world effectiveness. Learn why this gap exists and how HEOR uses real-world evidence (RWE) to correct for it.

An educational guide to QALYs and ICERs, the core metrics in health economics. Learn how they measure value and guide cost-effectiveness decisions.

Learn the economic principles behind million-dollar gene therapy pricing. This analysis compares one-time cure costs to lifetime chronic care using value-based

Learn how patient quality of life (QoL) data is quantified into Quality-Adjusted Life Years (QALYs) to perform cost-effectiveness analysis for specialty drugs.

Learn how real-world data (RWD) and evidence (RWE) are used to validate clinical trial assumptions in post-market economic models for HTA and reimbursement.

Learn how health economic data like cost-effectiveness analysis is used to secure drug formulary placement and reimbursement from payers and HTA bodies.

An overview of market access analytics covering its definition, scope, and role in helping pharmaceutical firms navigate complex payer reimbursement models. Updated for 2026 with IRA drug price negotiation impacts, agentic AI platforms, EU HTA harmonisation, and digital therapeutics reimbursement advances.